Actively Recruiting
Long-term Follow-up of Subjects Treated With CAR T Cells
Led by Marcela V. Maus, M.D.,Ph.D. · Updated on 2026-03-16
45
Participants Needed
1
Research Sites
834 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).
CONDITIONS
Official Title
Long-term Follow-up of Subjects Treated With CAR T Cells
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provision of voluntary written informed consent by subject
- CAR T cells were administered in DF/HCC IRB corresponding main study
You will not qualify if you...
- Subject unable to comply with study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
M
Matthew J Frigault, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here